 
 |
|
U.S. Life Science Companies Raise $53 Million Through Activity of 19 At-the-Market (ATMs) Offerings in First Quarter of 2011, Data From Brinson Patrick Securities Show
Date: June 23, 2011
Client: Brinson Patrick Securities Corporatio
Summary: NEW YORK CITY, June 22, 2011 - Life sciences companies in the U.S. raised $53 million through activity of 19 at-the-market (ATM) offerings of common stock in the first quarter of this year, according to data released today from Brinson Patrick Securities Corp. The dollar amount represents a 32% increase in the use of ATMs in the life sciences sector compared to the first quarter of 2010. Four new ATMs were activated in the first quarter, 2011, and six new ATMs so far in the second quarter, 2011.
|
|
|
|
 |
|
Ambrx to Present Data from Antibody Drug Conjugate Program at Upcoming Scientific Conferences
Date: April 22, 2011
Client: Ambrx Inc.
Summary: SAN DIEGO, June 22, 2011 /PRNewswire/ -- Ambrx Inc. today announced that Ho Cho, Ph.D., the company's Chief Technology Officer, will present preclinical data from the company's antibody drug conjugate (ADC) programs at five upcoming scientific conferences. The presentations will include data obtained from recent xenograft studies comparing Ambrx ADCs with those created using other technologies.
|
|
|
|
 |
|
AVI BioPharma Expands Clinical Pipeline With Initiation of Phase 1 Study of Influenza Therapeutic Candidate
Date: June 21, 2011
Client: AVI BioPharma, Inc.
Summary: BOTHELL, WA, Jun 21, 2011 (MARKETWIRE via COMTEX) -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced that it initiated dosing of volunteers in a Phase 1 clinical study of AVI-7100, the Company's lead drug candidate for the treatment of influenza. AVI-7100 is a therapeutic candidate with a novel mechanism of action and potentially broad-spectrum activity against influenza viruses, including Tamiflu-resistant virus strains. This clinical trial is the third Phase 1 program initiated this year for an AVI infectious disease drug candidate.
|
|
|
|
 |
|
LifeCycle Pharma Announces Positive Phase III Results: LCP-TacroTM Trial in Stable Kidney Transplant Patients Meets all Primary Efficacy and Safety Endpoints
Date: June 21, 2011
Client: LifeCycle Pharma A/S
Summary: LifeCycle Pharma A/S (OMX:LCP) today reported that the company's lead product candidate, LCP-Tacro™, successfully demonstrated non-inferiority compared to tacrolimus (Prograf®; Astellas Pharma) in its Phase III trial, Study 3001. The Phase III Open-label conversion (switch) study in 326 stable kidney transplant recipients, with Prograf® as the comparator, met its primary efficacy and primary safety endpoints.
|
|
|
|
 |
|
ACT Announces First Patients Enrolled in Two Clinical Trials Using Embryonic Stem Cells to Treat Stargardt’s Disease and Dry Age-Related Macular Degeneration
Date: June 16, 2011
Client: Advanced Cell Technology, Inc.
Summary: MARLBOROUGH, Mass. - June 16, 2011 - Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today the enrollment of the first patients in its two Phase 1/2 clinical trials for Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (Dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patients were enrolled at the Jules Stein Eye Institute at the University of California, Los Angeles (UCLA).
|
|
|
|
 |
|
Reata and Abbott Initiate Global Phase 3 Study of Bardoxolone Methyl in Patients with Chronic Kidney Disease and Type 2 Diabetes
Date: June 16, 2011
Client: Reata Pharmaceuticals, Inc.
Summary: IRVING, Texas and ABBOTT PARK, Ill., June 16, 2011 /PRNewswire/ -- Reata Pharmaceuticals, Inc. and Abbott announced today the initiation of a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of bardoxolone methyl in patients with chronic kidney disease (eGFR of 15-29 mL/min/1.73 m2) and type 2 diabetes.
|
|
|
|
 |
|
Small Molecule Simplicity Gives Them Staying Power
Date: June 15, 2011
Client: Cempra Pharmaceuticals, Arena Pharmaceuticals
Summary: There is a profound association between cancer and inflammatory processes, according to Raffaella Sordella, Ph.D., assistant professor at Cold Spring Harbor Laboratory. Dr. Sordella was a keynote speaker at CHI’s recent conference on drug discovery chemistry.
|
|
|
|
 |
|
After Lengthy Delay, Polaris Ready To Take HCC Drug Into Phase III
Date: June 14, 2011
Client: Polaris Pharma
Summary: More than three years after completing a successful Phase II trial in hepatocellular carcinoma, Polaris Pharma has obtained a special protocol assessment (SPA) with FDA and plans to go forward this summer with a Phase III trial of its experimental biologic, ADI-PEG 20 (pegylated arginine deiminase).
|
|
|
|
|
|
AVI BioPharma Names Ed Kaye, M.D., Chief Medical Officer
Date: June 6, 2011
Client: AVI BioPharma, Inc.
Summary: BOTHELL, WA, Jun 06, 2011 (MARKETWIRE via COMTEX) -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today the appointment of Ed Kaye, M.D., as Chief Medical Officer effective June 20, 2011. The addition of Dr. Kaye, a recognized industry leader in the development of therapeutics for the treatment of rare genetic diseases, and an expert in pediatric neurological diseases, continues AVI's strategy in assembling an executive team with industry-leading experience.
|
|
|
|
 |
|
Argos Therapeutics Presents New Phase 2 Data Showing its Arcelis™ Immunotherapy AGS-003 in Combination with sunitinib Improves Progression-Free Survival (PFS) in Patients with Advanced Renal Cell Carcinoma (RCC)
Date: June 5, 2011
Client: Argos Therapeutics
Summary: DURHAM, N.C., June 5, 2011 /PRNewswire/ -- Argos Therapeutics today announced that new data from its Phase 2 combination study of its Arcelis™ immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib showed improvement over expectations for sunitinib alone in progression-free survival (PFS) in newly diagnosed metastatic RCC patients with unfavorable prognosis. Induction of anti-tumor (CD28+) memory T cell responses correlated with PFS and all patients that were analyzed in the study demonstrated a decrease in circulating regulatory T cells. There were no safety issues or additive toxicity of AGS-003 in combination with sunitinib. Data were presented by Dr. Robert Figlin, director of the Division of Hematology/Oncology at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, in a poster and a discussion session at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
|
|
|
|
 |
|
Endocyte's EC145 Meets Primary Endpoint in Phase 2 Study, Demonstrating 85 Percent (2.3 month) Improvement in Median Progression-Free Survival for Treatment of Platinum Resistant Ovarian Cancer
Date: June 5, 2011
Client: Endocyte, Inc.,
Summary: WEST LAFAYETTE, Ind., June 5, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the Phase 2 PRECEDENT trial, investigating the company's lead drug candidate, EC145, in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer, met its primary endpoint by showing an 85 percent, 2.3 month, improvement in median progression-free survival (PFS) in the intent-to-treat population and a 260 percent, 4.0 month, improvement in a subset of folate receptor positive patients. EC145 in combination with PLD showed limited additional toxicity compared to standard therapy with PLD alone. The most commonly occurring adverse events were neutropenia, small intestine obstruction, and palmar-plantar erythrodysesthesia. EC145 is a therapeutic that targets the folate receptor and EC20 is a companion imaging diagnostic used to assess folate receptor presence.
|
|
|
|
 |
|
AVI Biopharma CEO Chris Garabedian Seeks to Avoid Quick Flip, Build Enduring Drug Company
Date: June 2, 2011
Client: AVI Biopharma
Summary: Chris Garabedian took his first shot at being a CEO last December. Immediately, people thought this was a little bit crazy.
|
|
|
|
 |
|
Potential for Developing Fusidic Acid (TAKSTA™, CEM-102) in the U.S. is Profiled in Clinical Infectious Disease
Date: June 1, 2011
Client: Cempra Pharmaceuticals
Summary: CHAPEL HILL, N.C., June 1, 2011 – Cempra Pharmaceuticals, a developer of differentiated antibiotics, announced the publication of a Clinical Infectious Disease supplement (Vol. 52, Supplement 7) that profiles fusidic acid and specifically TAKSTATM (CEM-102), administered using a proprietary loading dose regimen, for use in treating acute bacterial skin and skin structure infections (ABSSSI) in the U.S.
|
|
|
|
 |
|
Additional Data From Multiple Phase 1 and 2 Studies of S*BIO's Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
Date: June 1, 2011
Client: S*BIO Pte Ltd
Summary: SINGAPORE, June 1, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced that additional data from multiple Phase 1 and 2 clinical studies of its novel JAK2 inhibitor SB1518 further confirmed safety and efficacy for the treatment of patients with symptomatic myelofibrosis (MF) and enlarged spleens. In the studies, SB1518 alleviated MF-associated splenomegaly and showed no evidence of myelosuppression and no exacerbation of cytopenias. Results will be presented at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago and the 16th Congress of the European Hematology Association (EHA) in London.
|
|
|
|
|
|
Argos Therapeutics’ Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination with Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
Date: June 1, 2011
Client: Argos Therapeutics
Summary: DURHAM, N.C. – June 1, 2011 – Argos Therapeutics announced today that its ArcelisTM immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib demonstrated a strong immunologic response that correlated to improved clinical outcomes. The Phase 2 combination study in newly diagnosed, metastatic RCC patients with unfavorable prognosis demonstrated decreases in T regulatory cells, along with a concurrent expansion of CD28+ memory cytotoxic T lymphocytes (CTL). Results will be presented by Dr. Robert Figlin, director of the Division of Hematology/Oncology at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, in a poster and a discussion session at 8 a.m. CDT, and noon CDT, respectively, Saturday, June 4, 2011, at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
|
|
|
|
|
